Renal clear cell carcinoma (ccRCC) is the most typical pathological type of renal carcinoma (RCC), accounting for about 75%. The pathogenesis of ccRCC is a complex process in which multiple factors or multiple gene variations act together and affect each other. With the deepening research of ccRCC and the development of next-generation sequencing, genomics has been recognized and widely used in cancer research. At present, the mutant gene map of renal clear cell carcinoma has been obtained by high-throughput targeted sequencing, in which the mutant gene BAP1 is a typical tumor suppressor gene. Studies have found that the mutation of BAP1 is closely related to the development and progression of ccRCC. BAP1 mutation is ubiquitous in ccRCC, and has attracted more and more scholars' research interest. Fruitful research results have been obtained, which is of great significance for the early diagnosis and targeted therapy of ccRCC. BAP1 may play a protective role in the development of CCRCC, and its mutation is a marker of poor prognosis in CCRCC. The pathogenesis, proliferation, biological activity, clinical stage and prognosis of renal clear cell carcinoma are all related to the expression and function of BAP1. BAP1 plays an important role in the development of renal clear cell carcinoma.

Ting Pan, Peng Cheng. Correlation analysis between renal clear cell carcinoma and BAP1. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 3: 72-76. https://doi.org/10.25236/IJFM.2023.050313.

[1] Motzer, R. J., et al., Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in oncology. J Natl COMPR Canc Netw, 2017. 15 killers: p. 804-834.

[2] FAN S J, Li X, TIE l, et al. KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin [J]. Oncotarget, 2016, 7(12): 13520-13537.

[3] Yeh I J, Chen S C, Yen M C, et al. 6-shogaol suppresses 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (Phip)-induced human 786-O renal cell carcinoma osteoclastogenic activity and metastatic potential [J]. Nutrients, 2019, 11(10): 2306.

[4] Eletr Z M, Yin l, Wilkinson K D, et al., BAP1 is phosphorylatedat serine 592in S - phase following DNA damage [J]. FEBS Lett, 2013, 587(24): 3906-3911.

[5] Yuwaraj, Kadariya, Mitchell, et al. BAP1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline BAP1 mutations. [J]. Cancer Research, 2016.

[6] Jim énez-valerio, G., et al., Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and patients. Cell Rep, 2016. 15 killers: p. 1134-43.

[7] Wang s, Gu y f, Wolff N, et al. BAP1 is essential for kidney function and cooperates with VHL in renal tumorigenesis [J]. Proceedings of the National Academy of Sciences of the United States of, 2014, 111(46).

[8] Gerlinger M, Horswell s, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion Sequencing [J]. Nat Genet, 2014, 46(3):

[9] Yuwaraj, Kadariya, Mitchell, et al. BAP1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline BAP1 mutations. [J]. Cancer Research, 2016.

[10] Murali R, Wiesner T, Scolyer R A. Tumours associated with BAP1 mutations [J]. Pathology, 2013, 45(2): 116-126.

[11] Brugarolas J. PBRM1 and BAP1 as novel targets for renal Cell carcinoma [J]. Cancer J, 2013, 19(4): 324-332.

[12] Shen Chen. Expression of BAP1 in lung adenocarcinoma is associated with clinical prognosis and tumor invasion Relevance Studies [D]. Shanghai: Fudan University, 2014.

[13] Piva F, Giulietti m, Occhipinti G, et al.. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma [J]. Oncotarget, 2015, 6(31): 32161-32168.

[14] Wang S S, Gu Y F, Wolff N, et al. BAP1 is essential for kidney function and cooperates with VHL in renal tumorigenesis [J]. Proc NATL Acad Sci, 2014, 111(46): 16538-16543.

[15] Hakimi A A, Ostrovnaya I, Reva B A, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 regulators epigenetic BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network [J]. Clin Cancer Res, 2013, 19(12): 3259-3267.

[16] Gao, X. and D. F. Mc Dermott, Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opin Bio Ther, 2018. 18(9): p. 947-957.

[17] Chung Tung. Functional studies of the deubiquitinase BAP1 in hepatocellular carcinoma development, Chin Med Biotechnol, 2021, 16(5): 407-418

[18] Hirsch TZ, Negulescu A, Gupta B, et al. BAP1 mutations define a subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. J Hepatol, 2020, 72(5): 924-936.

[19] Gao W, Li W, Xiao T, et al. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/-clear cell renal carcinoma [J]. Proc NATL Acad Sci, 2017, 114(5): 1027-1032.

[20] Carbone M, Yang H, Pass H I, et al., BAP1 and cancer [J]. Nat Rev Cancer, 2013,13(3): 153-159.

[21] Brugarolas J. PBRM1 and BAP1 as novel targets for renal cell carcinoma [J]. Cancer Journal (Sudbury, Mass), September 4, 2013: 324-32.

[22] Kapur P, PENA-LLOPIS s, Christie A, et al., Effects on survival of BAP1and PBRM1 mutations sporadic in clear-cell renal-cell carcinoma: a retrospective analysis with independent validation [J]. The Lancet Oncology, 2013, 14(2): 159-67.

[23] PE A-Llopis s, s Vega-Rub ín-de-celis, Liao A, et al., Erratum: BAP1 loss defines a new class of renal cell carcinoma [J]. Nature Genetics, 2012, 44(9): 1072-1072.

[24] Kapur P, Christie A, Raman JD, et al., BAP1 immunohistochemistry in a multi-institutional cohort predicts outcomes in patients with clear cell renal cell carcinoma [J]. J UROL, 2014, 191(3): 603-610.

[25] Joseph RW, Kapur P, Serie DJ, et al., Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma [J]. Cancer, 2014, 120(7): 1059-1067.

[26] Zhang Hongxiu, Nie Mingxiu, Yang Hua, etc., Ubiquitin proteasome pathway and its role in renal cell carcinoma Research progress in [J]. Acta Kunming University of Science and Technology: Natural Sciences, 2015, 40(4): 84-90.

[27] Wunderlich R, Ruehle PF, DELOCH L, et al., Interconnection between DNA damage, senescence, inflammation, and cancer [J]. Front Biosci, 2017, 22: 348-369. DOI: 10.2741/4488.

[28] Bilusic m, Girardi D, Zhou y, Jung K, Pei J, Slick M, Chen Q, Meerzaman d, Alpaugh K, Young D, Flieder D, Gray P, Plimack E. Molecular Profiling of Responders Exceptional T O Cancer therapy. Oncologist. 2021MAR; 26(3): 186-195.

[29] Wu Ying, Li Xueying, Pan youfu. BAP1 and its inhibitory effect on clear cell renal cell carcinoma [J]. Journal of the Zunyi Medical University, 2019, 42(5): 8.

[30] Li Mingzi, Deng Zheng, Chen Mulin, etc., Experimental study of BRCA1-related protein 1 on proliferation and invasion of renal cell carcinoma [J]. Advances in modern biomedicine, 2019(24): 5.